Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 282

1.

Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial.

Midgley RS, McConkey CC, Johnstone EC, Dunn JA, Smith JL, Grumett SA, Julier P, Iveson C, Yanagisawa Y, Warren B, Langman MJ, Kerr DJ.

J Clin Oncol. 2010 Oct 20;28(30):4575-80. doi: 10.1200/JCO.2010.29.6244. Epub 2010 Sep 13.

PMID:
20837956
2.

Sudden death in patients receiving drugs tending to prolong the QT interval.

Jolly K, Gammage MD, Cheng KK, Bradburn P, Banting MV, Langman MJ.

Br J Clin Pharmacol. 2009 Nov;68(5):743-51. doi: 10.1111/j.1365-2125.2009.03496.x.

3.

Psychotropic medication: curing illness or creating problems?

Jolly K, Langman MJ.

Heart. 2009 Dec;95(23):1893-4. doi: 10.1136/hrt.2009.179127. Epub 2009 Sep 23. No abstract available.

PMID:
19778922
4.

Is thiosulfate sulfurtransferase the colonic sulfide oxidase?

Eggo MC, Warrack R, Ramasamy S, Langman MJ, Singh S.

Dig Dis Sci. 2008 Mar;53(3):862. Epub 2007 Sep 1. No abstract available.

PMID:
17763981
5.

Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.

Kerr DJ, Dunn JA, Langman MJ, Smith JL, Midgley RS, Stanley A, Stokes JC, Julier P, Iveson C, Duvvuri R, McConkey CC; VICTOR Trial Group.

N Engl J Med. 2007 Jul 26;357(4):360-9.

6.

Impaired detoxication of hydrogen sulfide in ulcerative colitis?

Picton R, Eggo MC, Langman MJ, Singh S.

Dig Dis Sci. 2007 Feb;52(2):373-8. Epub 2007 Jan 11.

PMID:
17216575
7.

Antihypertensive medication and the risk of acute pancreatitis: the European case-control study on drug-induced acute pancreatitis (EDIP).

Eland IA, Sundström A, Velo GP, Andersen M, Sturkenboom MC, Langman MJ, Stricker BH, Wiholm B; EDIP Study Group of the European Pharmacovigilance Research Group.

Scand J Gastroenterol. 2006 Dec;41(12):1484-90.

PMID:
17101581
8.

Sulfide-detoxifying enzymes in the human colon are decreased in cancer and upregulated in differentiation.

Ramasamy S, Singh S, Taniere P, Langman MJ, Eggo MC.

Am J Physiol Gastrointest Liver Physiol. 2006 Aug;291(2):G288-96. Epub 2006 Feb 23.

9.

Systemic hypertension and glaucoma: mechanisms in common and co-occurrence.

Langman MJ, Lancashire RJ, Cheng KK, Stewart PM.

Br J Ophthalmol. 2005 Aug;89(8):960-3.

10.
11.

Initiation of antihypertensive therapy among new users of cyclooxygenase-2-selective and nonselective NSAIDs.

Langman MJ, Eichler HG, Mavros P, Watson DJ, Kong SX.

Int J Clin Pharmacol Ther. 2004 May;42(5):260-6.

PMID:
15176648
13.

Postmarketing surveillance of the safety of cimetidine: 15-year mortality report.

Beresford J, Colin-Jones DG, Flind AC, Langman MJ, Lawson DH, Logan RF, Paterson KR, Vessey MP.

Pharmacoepidemiol Drug Saf. 1998 Sep;7(5):319-22.

PMID:
15073978
14.

The burdens imposed by Crohn's disease: messages for clinicians?

Langman MJ.

Dig Liver Dis. 2003 Dec;35(12):849-50. No abstract available.

PMID:
14703878
15.
16.
17.
21.

Oestrogen-induced apoptosis in colonocytes expressing oestrogen receptor beta.

Qiu Y, Waters CE, Lewis AE, Langman MJ, Eggo MC.

J Endocrinol. 2002 Sep;174(3):369-77.

PMID:
12208656
22.

Controversies in COX-2 selective inhibition.

Simon LS, Smolen JS, Abramson SB, Appel G, Bombardier C, Brater DC, Breedveld FC, Brune K, Burmester GR, Crofford LJ, Dougados M, DuBois RN, Fitzgerald GA, Frishman W, García Rodríguez LA, Hochberg MC, Kalden JR, Laine L, Langman MJ, Prescott SM, van de Putte LB, Whelton A, White WB, Willaims GH.

J Rheumatol. 2002 Jul;29(7):1501-10. Review. No abstract available.

PMID:
12136912
23.

NSAIDs and gastrointestinal cancer prevention.

Jolly K, Cheng KK, Langman MJ.

Drugs. 2002;62(6):945-56. Review.

PMID:
11929340
24.

Ketorolac, diclofenac, and ketoprofen are equally safe for pain relief after major surgery.

Forrest JB, Camu F, Greer IA, Kehlet H, Abdalla M, Bonnet F, Ebrahim S, Escolar G, Jage J, Pocock S, Velo G, Langman MJ, Bianchi PG, Samama MM, Heitlinger E; POINT Investigators.

Br J Anaesth. 2002 Feb;88(2):227-33.

25.

Sulphide-induced energy deficiency in colonic cells is prevented by glucose but not by butyrate.

Hulin SJ, Singh S, Chapman MA, Allan A, Langman MJ, Eggo MC.

Aliment Pharmacol Ther. 2002 Feb;16(2):325-31.

26.

Mucosal protection against sulphide: importance of the enzyme rhodanese.

Picton R, Eggo MC, Merrill GA, Langman MJ, Singh S.

Gut. 2002 Feb;50(2):201-5.

27.

Which PPI?

Langman MJ.

Gut. 2001 Aug;49(2):309-10. No abstract available.

28.
29.

Heparin therapy for ulcerative colitis? Effects and mechanisms.

Michell NP, Lalor P, Langman MJ.

Eur J Gastroenterol Hepatol. 2001 Apr;13(4):449-56. Review.

PMID:
11338079
30.

Drug treatment of non-variceal upper gastrointestinal bleeding.

Langman MJ.

Baillieres Best Pract Res Clin Gastroenterol. 2000 Jun;14(3):357-64. Review.

PMID:
10952802
31.
32.
33.

Escherichia coli for ulcerative colitis.

Langman MJ, Allan RN.

Lancet. 1999 Dec 4;354(9194):2000-1. No abstract available.

PMID:
10622327
34.

Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs.

Weil J, Langman MJ, Wainwright P, Lawson DH, Rawlins M, Logan RF, Brown TP, Vessey MP, Murphy M, Colin-Jones DG.

Gut. 2000 Jan;46(1):27-31.

35.

Prospective, double-blind, placebo-controlled randomized trial of cimetidine in gastric cancer. British Stomach Cancer Group.

Langman MJ, Dunn JA, Whiting JL, Burton A, Hallissey MT, Fielding JW, Kerr DJ.

Br J Cancer. 1999 Dec;81(8):1356-62.

36.

Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.

Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ.

JAMA. 1999 Nov 24;282(20):1929-33.

PMID:
10580458
37.

Risks of anti-inflammatory drug-associated damage.

Langman MJ.

Inflamm Res. 1999 May;48(5):236-8. Review.

PMID:
10391110
38.

Epidemiology of non-steroidal anti-inflammatory drug damage to stomach and duodenum.

Langman MJ.

Ital J Gastroenterol Hepatol. 1999;31 Suppl 1:S2-5. Review.

PMID:
10379462
39.

Loss of estrogen inactivation in colonic cancer.

English MA, Kane KF, Cruickshank N, Langman MJ, Stewart PM, Hewison M.

J Clin Endocrinol Metab. 1999 Jun;84(6):2080-5.

PMID:
10372714
40.

Omeprazole in the treatment of ulcers induced by NSAIDs.

Langman MJ.

Gut. 1998 Dec;43(6):744-6. No abstract available.

41.

Communication among health professionals. Poor communication puts patients at risk.

Salter R, Brettle P, Hobbs FD, Langman MJ.

BMJ. 1998 Jul 25;317(7153):279-80. No abstract available.

42.

Expression of oestrogen receptor and oestrogen-inducible genes pS2 and ERD5 in large bowel mucosa and cancer.

Singh S, Poulsom R, Hanby AM, Rogers LA, Wright NA, Sheppard MC, Langman MJ.

J Pathol. 1998 Feb;184(2):153-60.

PMID:
9602706
43.
44.

European network for the case-population surveillance of rare diseases (Euronet). A prospective feasibility study.

Capellà D, Laporte JR, Vidal X, Wiholm BE, Bégaud B, Langman MJ, Rawlings M.

Eur J Clin Pharmacol. 1998 Jan;53(5):299-302.

PMID:
9516026
45.
46.

Homoeopathy trials: reason for good ones but are they warranted?

Langman MJ.

Lancet. 1997 Sep 20;350(9081):825. No abstract available.

PMID:
9310595
47.

Expression of oestrogen receptor and oestrogen-inducible genes in pancreatic cancer.

Singh S, Baker PR, Poulsom R, Wright NA, Sheppard MC, Langman MJ, Neoptolemos JP.

Br J Surg. 1997 Aug;84(8):1085-9.

PMID:
9278646
48.

Differential expression of oestrogen receptor and oestrogen inducible genes in gastric mucosa and cancer.

Singh S, Poulsom R, Wright NA, Sheppard MC, Langman MJ.

Gut. 1997 Apr;40(4):516-20.

49.

Chronic inflammatory bowel disease: uniformity or diversity of impact in Europe.

Langman MJ.

Eur J Gastroenterol Hepatol. 1997 Apr;9(4):331-2. Review. No abstract available.

PMID:
9160193
50.

Insulin-like growth factor binding proteins as mediators of IGF-I effects on colon cancer cell proliferation.

Michell NP, Dent S, Langman MJ, Eggo MC.

Growth Factors. 1997;14(4):269-77.

PMID:
9386991

Supplemental Content

Loading ...
Support Center